Bringing together vaccinia’s natural attributes with novel genetic engineering, Genelux has designed its proprietary vaccinia virus-based vectors to deliver a four- pronged attack against cancer:

Genelux has pioneered a new therapeutic and diagnostic product platform utilizing an attenuated (Lister strain) oncolytic vaccinia virus to specifically enter and destroy solid tumors and distant metastases without harming healthy tissues and organs. Genelux believes that vaccinia virus is one of the most promising oncolytic viruses currently being tested in human clinical trials and has selected it as a backbone for its novel cancer therapies and diagnostics.

1. Highly specific replication in and lysis of tumor cells


Genelux vaccinia-based oncolytic viral platform takes advantage of the virus natural selectivity to enter and replicate within tumors and metastases. The intravenously-delivered virus travels through the bloodstream, infects and replicates within tumor cells. Tumor cells are killed (lysed) as the amplifying viral load causes the cells to burst and viral progeny to infect neighboring tumor cells. The process continues until there are no more tumor cells remaining.

2. Destruction of Tumor Vasculature

The network of blood vessels surrounding a tumor that once fueled the cancer’s growth is destroyed as the oncolytic process results in production of chemokines and cytokines, which attract neutrophils to the tumor, causing intravascular thrombosis and avascular Necrosis. Vaccinia strains are also capable of infecting tumor-associated endothelial cells whose destruction may also contribute to vascular collapse.

3. Activation of the innate and adaptive immune response against tumors

In addition to direct lysis (killing) of tumor cells, the Genelux technology also harnesses the body’s innate and adaptive immune response in the fight against cancer; in fact, our research shows that the immune system ultimately induces clearance of virally infected tumors, much in the way immune-mediated tissue rejection occurs. Moreover, preclinical evidence suggests that this process can train the body’s immune system to inhibit the formation of future tumors.

4. Armed with your favorite genes (YFGs) for specific delivery and amplification in tumor cells to achieve potent anti-cancer therapy and diagnosis

Genelux specializes in the development of customized viral vectors that carry desired transgenes (genetic material) to be manufactured or over-expressed directly within the tumor for a number of specific purposes:

     Imaging (Optical and Deep tissue cancer diagnosis staging, monitoring of therapy, Intra-operative aid)
     Immuno-modulation (Stimulating or temporarily suppressing an immune response to aid anti-cancer therapy; or serving to minimize the unwanted side effects of chemotherapy during combination viral and chemotherapy)

Genelux works actively with leading universities, medical centers and prospective pharma partners to efficiently produce viral vectors incorporating new genes and proteins to yield highly targeted, more effective and safer cancer therapies.